Type 1 Diabetes (T1D)DMBCOGNCT07164768
Cognitive Function and Mental Health in Children and Youth With Type 1 Diabetes (T1D)
An observational study of Type 1 Diabetes (T1D), run by Hirabai Cowasji Jehangir Medical Research Institute at 1 site in India.
Trial summary
The Hirabai Cowasji Jehangir Medical Research Institute (HCJMRI), Pune, a Center of Excellence in type 1 diabetes (T1D), has extensive experience in studying prospective cohorts with high follow-up rates. Read more about this study
- Who is it for?
- Ages 10 to 21 yearsHealthy volunteers can take part
- Conditions the study is for
- Type 1 Diabetes (T1D)
- How many people
- 400 participants
- Where
- 1 siteIndia
- Study dates
- 25 Jun 2024to 25 Jun 2027
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 21 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: Study Subjects: The Hirabai Cowasji Jehangir Medical Research Institute, which is a sister concern of Jehangir hospital, Pune, has been involved in health related programs since its inception in 1995. Our major areas of work include Nutritional and Growth Disorders in Children, Type 1 Diabetes, Maternal and Child Health, Osteoporosis and Bone Health, Psychological Counseling, HIV and Cancers. Cases: There are 738 children registered with HCJMRI for the treatment and management of type 1 diabetes. The 'Sweetlings' programme is a charity clinic that provides holistic care to underprivileged children and youth with Type 1 Diabetes Mellitus (T1D). Currently, the clinic supports 548 children and youth with T1D aged 0 to 22 years in the Pune region of the Western Indian State of Maharashtra. From these, we have 386 children who are between 10-21 years of age. Controls: Siblings of these T1D children will be included as healthy age-matched controls for participation in this study. This wil
Who may be able to join
- Children, adolescents and young adults with T1D and their parents (caregiver, either mother or father)
Who cannot join
- Both parents are not alive or the child is not living with the parents and living with the grandparents.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
India1 site
Hirabai Cowasji Jehangir Medical Research Institute
Pune, Maharashtra, 411001
About this study
Official title: Cognitive Function and Mental Health in Children and Youth With Type 1 Diabetes (T1D) and Its Determinants
The Hirabai Cowasji Jehangir Medical Research Institute (HCJMRI), Pune, a Center of Excellence in type 1 diabetes (T1D), has extensive experience in studying prospective cohorts with high follow-up rates. HCJMRI maintains a registry of over 800 children with T1D, systematically assessing their glycemic control and diabetes-related complications.
Given the high prevalence of T1D in India and the lack of studies on Indian children with T1D, the investigators aim to investigate cognitive function and mental health in children and youth with T1D compared to healthy controls, exploring key determinants of these outcomes.
Read more
The investigators propose a cross-sectional, observational, case-control study involving children and youth aged 10-21 years with T1D and age- and gender-matched healthy controls from similar socio-economic backgrounds. Participants will be enrolled between July 2023 and July 2025, with assent from children and consent from parents. Those with neurodevelopmental disorders will be excluded. The investigators plan to recruit one in two eligible participants with T1D from our existing cohort, with a total sample size of 396 participants (264 cases and 132 controls), adequately powered to detect group differences with a moderate effect size.
Data on T1D exposure will be extracted from ongoing cohort records. Outcomes assessed in both groups include:
- Cognitive functions - assessed using age-appropriate tests.
- Behavioral and emotional problems - evaluated in children, adolescents, and young adults.
- Quality of life - assessed using standardized tools. Potential confounders such as age, gender, socio-economic status, parental education, occupation, participant's education, and pubertal status will be considered. Random blood samples will be collected at the time of cognitive testing to measure plasma glucose, HbA1c, and Human-BDNF levels, examining associations between glycemic control and cognitive outcomes. Additionally, annual checkup data will be used to explore the impact of T1D complications on cognitive function.
Group differences in outcomes will be analyzed using ANCOVA while controlling for covariates. Regression models will assess cognitive function as a function of T1D exposure, adjusting for mediators and modifiers.
This will be one of the first studies in India to systematically examine multiple cognitive domains in a large T1D sample across a broad age range (10-21 years). Findings will enhance understanding of T1D's impact on cognitive development in an Indian context, where undernutrition is common, and T1D prevalence is rising.
Keywords: Type 1 diabetes, children, cognitive function, behavioral and emotional problems, quality of life.
Read the detailed description
Objectives of the project:
- To assess cognitive function in children with T1D in comparison with healthy controls and its determinants (parental education and occupation, parenting style and mental health of parents)
- To study the association of parental education and occupation, parenting style and mental health of parents with child's glycemic control in children with T1D
- To assess the stress, anxiety and depression in children, adolescents and young adults with T1D (10-21 years) in comparison with healthy controls and its impact on their quality of life
- Methodology:
Study Subjects:
The 'Sweetlings' programme which is a charity clinic that provides holistic care to underprivileged children and youth with Type 1 Diabetes Mellitus (T1D). Currently, the clinic supports 548 children and youth with T1DM aged 0 to 22 years in the Pune region of the Western Indian State of Maharashtra.
The investigator have 382 children between 6-18 years of age and 103 who are between 18-22 years of age. Siblings of these T1D children will be included as healthy age matched controls for participation in this study. This will ensure about the age matching and also their socioeconomic status and family environment will be similar.
Sample size estimations:
The investigator expects to recruit one in two of participant with type 1 diabetes from our cohort and age gender matched healthy controls without type 1 diabetes. Sample size estimation suggests a sample size of 396 participants (264 cases and 132 controls) would be adequately powered to detect group differences with moderate effect size.
Procedure:
Institutional ethics committee approval will be obtained for the study. Children with T1D will be approached for participation and information about the study will be provided. T1D children and their parents will be recruited after obtaining informed parental consent from children less than 12 years and parent consent and child's assent for those above 12 years of age. Informed consent will be obtained from those above 18 years of age.
Exposures:
Systematic assessments of the exposures (Type 1 diabetes, Birth weight, parental education, occupation, mental health, parenting style) will be performed in the cohort. This data of recruited subjects will be extracted from available records as well as collecting their current information using a standardized questionnaire.
Glucose values and HbA1c measured in the clinic at the time of neurocognitive testing will be taken to study the associations between the glycemic control in T1D children and their neurocognitive outcomes.
Additionally, Brain Derived Neurotrophic Factor (BDNF) which is a key molecule involved in neuroplastic changes related to learning and memory will also be measured.
Outcomes:
Cognitive function and mental health of children, adolescents and young adults with T1D Following measurements will be performed in T1D children based on their age at assessment.
- Neurocognitive measurements: Global measures of intelligence was assessed using the Raven's progressive Matrices.
- Mental health in children and parents: Depression, anxiety and stress related information will be collected using specific questionnaires.
- Quality of life in children and parents using Peds QL standardised modules and questionnaires.
Cognitive function assessments (general intellectual test, IQ):
- Raven's Colored Progressive Matrices: Raven's Progressive Matrices (often referred to simply as Raven's Matrices) or RPM is a non-verbal test typically used to measure general human intelligence and abstract reasoning and is regarded as a non-verbal estimate of fluid intelligence.
- Speed: Finger tapping: It is the measure of motor speed. Age range: 9 years and above The finger-tapping test consists of an especially adopted electric finger-tapping instrument and monitor to read the number of taps.
- Attention: d2: It is a refinement of the cancellation test. Age range 9-60 years.
- Executive functioning:
- Verbal fluency: FAS test. Age range: Children: 5 to 15 years
- Animal names test: Age range: Children: 5 to 15 years
- COWA test (Controlled Oral Word Association test). Adults: 15 to 65 years
- Working memory: Digit and letter number (WISC). Age range: 6 to 16 years.
- Processing speed: Coding and symbol search (WISC). Age range: 6 to 16 years.
- Working memory: Digit and arithmetic (WAIS) [8] and Coding and symbol search (WAIS). Age range: 16 to 90 years
- Working Memory Index- subtests include Digit span and arithmetic. Processing Speed Index- subtests include symbol search, coding, and cancellation.
- Shift of set (Wisconsin card sorting test 64: Age range: 6 years 5 months to 89 years
- Response inhibition: Stroop test. Age range: Children: 5-14 years, Adults: 15 years and above
- Verbal learning and memory: Auditory verbal learning test (AVLT): Age range: Children: 5 to 15 years, Adults: 16 to 65 years
- Test of comprehension: Token test: Age range: Children: 5 to 15 years, Adults: 16 to 65 years
Mental health and quality of life in children and parents:
- CBCL (The Child Behavior Checklist): The 2001 revision of the CBCL, the CBCL/6-18 (used with children 6 to 18), is made up of eight syndrome scales:
- anxious/depressed
- depressed
- somatic complaints
- social problems
- thought problems
- attention problems
- rule-breaking behaviour
- aggressive behaviour
- BSI (Brief Symptom Inventory): The Brief Symptom Inventory (BSI) consists of 53 items covering nine symptom dimensions: Somatization, Obsession-Compulsion, Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic anxiety, Paranoid ideation and Psychoticism; and three global indices of distress: Global Severity Index, Positive Symptom Distress Index, and Positive Symptom Total. The global indices measure current or past level of symptomatology, intensity of symptoms, and number of reported symptoms, respectively.
- Quality of life:
Peds QL: The Pediatric Quality of Life Inventory (PedsQL): PedsQL Generic Core Scale will be used to measure generic health-related quality of life of the children, adolescents and young adults in this study. This scale is applicable for healthy school and community populations, as well as patient populations with acute and chronic health conditions.
Effect modifiers:
- Parents' mental health: This will be assessed using BSI questionnaire.
- Parenting style: The Parenting Styles and Dimensions Questionnaire (PSDQ)[19] is one measure that is widely utilized in current research to examine parenting styles.
- Parents' quality of life: PedsQL Generic Core Scale will be used to measure generic health-related quality of life of the primary caregiver (any one parent, either mother or father).
- Parental education and occupation: This information will be collected using standard questionnaires for general information.
- Scholastic performance: Academic exposure can positively impact cognitive functioning. This will be assessed by taking the average marks/grades obtained by the child in previous year academic performance.
Mediators:
- Glycemic control and complications of type 1 diabetes: The investigators regularly perform the annual checkups in our type 1 cohort. In that following measurements are performed to assess their glycemic control and development of micro and macrovascular complications.
- Human BDNF (Brain Derived Neurotrophic Factor): This will be measured using standard enzymatic method using Elabscience® Human BDNF (Brain Derived Neurotrophic Factor) ELISA Kit. Association between BDNF levels and cognitive functions will be studied.
- Growth and development: This data will be utilized from the anthropometric measurements performed at the time of their annual check-ups. Pubertal staging is performed by a pediatric endocrinologist or a medical officer. Information regarding age and date of menarche is also collected.
- Lifestyle (nutrition and physical activity): The investigators also collect the information regarding their nutritional intake using a 24-hour dietary recall and data regarding their physical activity levels using standard questionnaire. Using this data, the investigators can study the association between lifestyle with cognitive functions
Measurement of potential confounders:
- A semistructured proforma will be designed to collect socio-demographic information, current educational status, Parental education. Socio-economic status will be assessed using the Kuppuswamy 2023 coding and scale.
- Family history of neurodevelopmental/neurological/mental health disorders will be obtained on a three generation genogram.
- Pubertal status will be assessed on the Tanner's staging for Puberty by medical officer.
Future implications:
Early detection and intervention for cognitive impairment in the early stages of Type 1 Diabetes Mellitus (T1DM) can facilitate effective treatment. Cognitive impairment is closely linked to poor glycaemic control and associated metabolic disruptions in T1DM. Initiating the management of metabolic abnormalities during the initial phases of diabetes holds the potential to prevent cognitive impairment. It is essential to include cognitive impairment screening for individuals with T1DM alongside assessments for other recognised macro- and microvascular complications of diabetes.
In addition to evaluating children with T1D, conducting assessments for their parents, including an analysis of parenting styles and stress levels associated with managing their child's diabetes, allows for the strategic planning of interventions.
This holistic approach not only enhances parents' diabetes management but also contributes to improved glycaemic control in T1D children, thereby positively influencing their cognitive function.
Detecting and addressing cognitive impairment at an early stage not only aids in the effective management of diabetes in children but also plays a pivotal role in fostering improved career prospects and job opportunities for them. Additionally, this proactive approach contributes to an overall enhancement of their quality of life. The downstream effect of these positive outcomes includes a reduction in the health-related and economic burden faced by India.
- Conditions
- Type 1 Diabetes (T1D)
- Keywords
- Type 1 diabetes, children, cognitive function, behavioral and emotional problems, quality of life
- Medical subject headings
- Diabetes Mellitus, Type 1, Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Children and youth with type 1 diabetes (T1D) and their parents | The Hirabai Cowasji Jehangir Medical Research Institute (HCJMRI), Pune is a Center of Excellence in type 1 diabetes and has vast experience in studying prospective cohorts with good follow up rates. It also has a registry of more than 800 children with type 1 diabetes with systematic assessment of their glycemic control and micro and macrovascular complications due to type 1 diabetes. We would like to propose a cross sectional, observational, case control study in children with T1D and healthy controls of age 10-21 years (who give assent and parents give consent; children no neurodevelopmental disorders will be enrolled in the study) from similar socio-economic class as the children with diabetes. Approximate period of enrollment will be from July 2023 to July 2025. We expect to recruit one in two of participant with type 1 diabetes from our cohort and age gender matched healthy controls without type 1 diabetes. |
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess intelligent quotient (IQ) as a cognitive function in children and youth with type 1 diabetes
Age range: 4 to 90 years. Raven's Colored Progressive Matrices: Raven's Progressive Matrices (often referred to simply as Raven's Matrices) to measure general human intelligence and abstract reasoning and is regarded as a non-verbal estimate of fluid intelligence. The Raven's 2 is a nonverbal assessment of general cognitive ability, including the ability to formulate new concepts when faced with novel information, extract meaning out of confusion or ambiguity, and think clearly about complex situation and events. It comprises 60 multiple-choice questions, listed in order of increasing difficulty. This format is designed to measure the test taker's reasoning ability, the eductive ("meaning-making") component of Spearman's g (g is often referred to as general intelligence). It is a measure of verbal and nonverbal generalized cognitive ability.
Measured: 3 years
To assess speed as a cognitive function in children and youth with type 1 diabetes
Finger-Tapping Test Age Range: 9 years and above Procedure: The test uses an adapted electric finger-tapping instrument and monitor to record the number of taps. The participant taps a mounted key as rapidly as possible using the index finger of the dominant hand, followed by the non-dominant hand. Five consecutive 10-second trials are conducted for each hand. A 30-second break is given after the third trial to minimize fatigue. A practice trial is provided before the test begins.
Scoring: The number of taps per 10-second trial is recorded separately for each hand. The mean number of taps across five trials is calculated for each hand.
Material: Finger-tapping instrument and stopwatch Duration: 5 minutes
Measured: 3 years
To assess attention as a cognitive function in children and youth with type 1 diabetes
d2 Test of Attention Age Range: 9-60 years Procedure: The d2 test assesses selective attention and concentration. It can be administered individually or in groups using a single test form. The form includes sections for subject data, test scores, and a practice sample. The standardized test consists of 14 lines, each with 47 characters (total: 658 items). Participants scan each line and cross out all "d's" with two dashes. Each line is timed for 20 seconds.
Reliability \& Validity: The test demonstrates high reliability (r > 0.90) across various indices (TN, TN-E, CP) and is supported by extensive research.
Materials: 2 pencils (without erasers) and a stopwatch for the examiner. Duration: 10 minutes
Measured: 3 years
To assess phonemic fluency as an executive function in children with type 1 diabetes
FAS Test (Children: 5-15 years) - A phonemic fluency test measuring verbal fluency. Participants generate words beginning with F, A, and S (or Ka, Pa, Ma for non-English speakers) within one minute per letter. Proper nouns are excluded. Score: Total admissible words. Duration: ~5 minutes
Measured: 3 years
To assess category fluency as an executive function in children with type 1 diabetes
Animal Names Test (Children: 5-15 years) - A category fluency test where participants list as many animal names as possible in one minute, excluding fish, birds, and snakes. Score: Total unique words. Duration: ~5 minutes
Measured: 3 years
To assess phonemic fluency as an executive function in adolescents and youth with type 1 diabetes
COWA Test (Adults: 15-65 years) - A phonemic fluency test where participants generate words beginning with F, A, and S (or Ka, Pa, Ma). Proper nouns and repeated words with different suffixes are excluded. Score: Average new words over three trials. Duration: ~5 minutes
Measured: 3 years
To assess category fluency as an executive function in adolescents and youth with type 1 diabetes
Category Fluency: Animal Names Test (Adults: 15-65 years) - Same as the children's version, assessing category fluency. Score: Total unique words. Duration: ~5 minutes
Measured: 3 years
To assess working memory as an executive function in children with type 1 diabetes
Digit \& Letter-Number (WISC) and Processing Speed: Coding \& Symbol Search (WISC) Age Range: 6-16 years Developed in 2003, this scale assesses intellectual ability. The Working Memory Index (WMI) includes Digit Span, Letter-Number Sequencing, and Arithmetic (supplemental). The Processing Speed Index (PSI) includes Coding, Symbol Search, and Cancellation (supplemental).
Digit Span: The child repeats numbers in the same or reverse order. Letter-Number Sequencing: The child recalls numbers in ascending and letters in alphabetical order.
Symbol Search: The child scans a group to identify target symbols within a time limit.
Duration: 10 minutes
Measured: 3 years
To assess working memory as an executive function in adolescents and youth with type 1 diabetes
Working Memory \& Processing Speed (WAIS) Age Range: 16-90 years The WMI measures working memory, attention, concentration, and reasoning, while the PSI assesses the ability to scan, sequence, and process visual information quickly. Both indices involve cognitive decision-making beyond simple reaction time.
Duration: 20 minutes
Measured: 3 years
To assess Shift of set (Wisconsin card sorting test) as an executive function in children and youth with type 1
Wisconsin Card Sorting Test (WCST-64)
Age Range: 6 years 5 months to 89 years
The WCST-64 assesses abstract reasoning and executive functions, including cognitive flexibility, goal-directed behavior, planning, and impulse control. Unlike the full WCST, which uses 128 cards, the WCST-64 uses 64 cards. Participants match stimulus cards without explicit instructions, receiving feedback on correctness. The test generates psychometric scores on categories achieved, trials, errors, and perseverative errors.
Materials: Four stimulus cards, 64 response cards, and a record form.
Duration: 20-30 minutes
The WCST has demonstrated reliability and validity across various populations, including individuals with autism, stroke survivors, pediatric groups, and psychiatric patients.
Measured: 3 years
To assess Response inhibition as an executive function in children and youth with type 1 diabetes
Stroop Test
Age Range: Children (5-14 years), Adults (15+ years)
The Stroop Test measures response inhibition, assessing the ability to suppress habitual responses in favor of unusual ones. It evaluates cognitive flexibility and prefrontal function.
Participants are shown a sheet with color names ("Blue," "Green," "Red") printed in different ink colors. They first read the words column-wise as quickly as possible while the time is recorded. Next, they name the ink color instead of reading the word, with the time again recorded.
Score: The Stroop effect score is calculated as:
Stroop Effect Score = Time to name colors - Time to read words Uncorrected errors are recorded separately for both phases.
Duration: ~20 minutes
Measured: 3 years
To assess Verbal Learning and Memory as cognitive function in children and youth with type 1 diabetes
Verbal Learning \& Memory: Auditory Verbal Learning Test (AVLT)
Age Range: Children (5-15 years), Adults (16-65 years)
The AVLT assesses verbal learning and memory using word lists. Adapted by WHO for different cultures, it includes Lists A \& B with 15 familiar words each, translated into Kannada, Tamil, Telugu, and Hindi.
Words from List A are presented at a rate of one per second for five trials, with recall recorded after each trial. Then, List B is introduced as an interference task, followed by immediate recall of List A. After 20 minutes, delayed recall of List A is assessed without re-presentation. Finally, a recognition test is conducted by mixing List A words with new words, recording hits and errors. Words are presented in the participant's preferred language (mother tongue or English).
Duration: 15 minutes
Measured: 3 years
To assess Test of comprehension as cognitive function in children and youth with type 1 diabetes
Test of Comprehension: Token Test
Age Range: Children (5-15 years), Adults (16-65 years)
The Token Test assesses verbal comprehension using tokens that vary in color, size, and shape. Participants follow spoken instructions of increasing complexity. Squares and circles in two sizes and five colors are placed in a fixed arrangement. Instructions are given once per item, with up to two repetitions if needed.
Scoring: One point is awarded for correct responses, with a 0.5-point deduction per repetition. A trial is failed if the participant does not follow instructions after two repetitions. The maximum score is 36.
Duration: 20 minutes
Measured: 3 years
Secondary outcomes (5)
To assess mental health in children and youth with type 1 diabetes and their parents
CBCL (Child Behavior Checklist) Age Range: 6-18 years The CBCL is part of the Achenbach System of Empirically Based Assessment (ASEBA) and detects behavioral and emotional problems in children. It is completed by parents, while the Teacher's Report Form (TRF) is completed by teachers, and the Youth Self-Report (YSR) by the child. The CBCL/6-18 includes eight syndrome scales: Anxious/Depressed, Depressed, Somatic Complaints, Social Problems, Thought Problems, Attention Problems, Rule-Breaking Behavior, and Aggressive Behavior. These form two higher-order factors: Internalizing and Externalizing. Responses cover the past six months.
BSI (Brief Symptom Inventory) Age Range: 18 years and above The BSI has 53 items covering nine symptom dimensions, including Somatization, Obsession-Compulsion, Depression, Anxiety, and Psychoticism. It also includes three global indices measuring symptom severity, distress intensity, and total reported symptoms.
Measured: 3 years
To assess Diabetes related stress and quality of life in children and youth with type 1 diabetes
The PedsQL Diabetes Module is a standardized tool designed to assess diabetes-related quality of life in children and adolescents with diabetes. It evaluates the impact of diabetes on various aspects of daily life, including treatment barriers, adherence, worry, and communication with healthcare providers. The module is structured for self-report by children and proxy-report by parents, covering emotional, social, and physical challenges associated with diabetes management. By identifying specific areas of distress and difficulty, the PedsQL Diabetes Module helps healthcare professionals tailor interventions to improve both medical outcomes and overall well-being in pediatric diabetes patients.
Measured: 3 years
To assess parents' perception towards diabetes related stress and quality of life in their children
Diabetes related stress and quality of life in children and parents' perception towards quality of life in their children will be assessed using standard questionnaires developed by The PedsQL™ Diabetes Module is a specific module of the PedsQL™
Measured: 3 years
To assess general quality of life in children and youth with type 1 diabetes
PedsQL Generic Core Scale will be used to measure generic health-related quality of life of the children, adolescnts and young adults in this study. This scale is applicable for healthy school and community populations, as well as patient populations with acute and chronic health conditions.
Measured: 3 years
To assess general quality of life in parents of children and youth with type 1 diabetes
PedsQL Generic Core Scale[18] will be used to measure generic health-related quality of life of the primary caregiver (any one parent, either mother or father). This scale is applicable for healthy school and community populations, as well as patient populations with acute and chronic health conditions.
- Parental education and occupation: This information will be collected using standard questionnaires for general information.
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2025
- Study start25 Jun 2024
- Primary completion25 Jun 2027 (estimated)
- Study completion25 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Type 1 Diabetes (T1D)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 400 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Hirabai Cowasji Jehangir Medical Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Anuradha Khadilkar, Hirabai Cowasji Jehangir Medical Research Institute
- Investigators
- Dr. Sonali S Wagle, M.Sc, RD, PhD, Study chair, Hirabai Cowasji Jehangir Medical Research Institute, Pune, India
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07164768
- Sponsor's protocol ID
- JCDC/BHR/24/034
- Acronym
- DMBCOG
- Status last verified
- Sep 2025
- First submitted
- 6 Dec 2024
- Last updated
- 10 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The de-identified individual participant data (IPD) will be shared with qualified researchers. The shared data will include \[specify data types, e.g., demographics, clinical outcomes, etc.\]. Access will be granted to researchers with a scientifically sound proposal that has been reviewed and approved by an independent review board. Requests should be directed to \[provide contact information or system, e.g., "via email to the principal investigator, Dr. Anuradha Khadilkar\]. Data sharing will comply with applicable laws, regulations, and institutional policies to ensure privacy and data security.
Publications
Wagle-Patki S, Keerthi A, Potnis R, Daphal Y, Gondhalekar K, Nayak IK, Kajale N, Vaman Khadilkar A. MIND-T1D: study protocol for a multidimensional neurocognitive and psychological assessment of Indian children and young adults with type 1 diabetes. BMJ Paediatr Open. 2026 Oct 3;10(1):e005159. doi: 10.1136/bmjpo-2026-005159.
PubMed 42829215
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cognitive Function and Mental Health in Children and Youth With Type 1 Diabetes (T1D) and Its Determinants
- ClinicalTrials.gov ID
- NCT07164768
- Acronym / sponsor ID
- DMBCOG / JCDC/BHR/24/034
- Conditions
- Type 1 Diabetes (T1D)
- Keywords
- Type 1 diabetes, children, cognitive function, behavioral and emotional problems, quality of life
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Hirabai Cowasji Jehangir Medical Research InstituteUniversity, hospital or other
- Study start
- 25 Jun 2024 (actual)
- Primary completion
- 25 Jun 2027 (estimated)
- Study completion
- 25 Jun 2027 (estimated)
- First posted
- 10 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Hirabai Cowasji Jehangir Medical Research Institute (HCJMRI), Pune, a Center of Excellence in type 1 diabetes (T1D), has extensive experience in studying prospective cohorts with high follow-up rates. HCJMRI maintains a registry of over 800 children with T1D, systematically assessing their glycemic control and diabetes-related complications.
Given the high prevalence of T1D in India and the lack of studies on Indian children with T1D, the investigators aim to investigate cognitive function and mental health in children and youth with T1D compared to healthy controls, exploring key determinants of these outcomes.
The investigators propose a cross-sectional, observational, case-control study involving children and youth aged 10-21 years with T1D and age- and gender-matched healthy controls from similar socio-economic backgrounds. Participants will be enrolled between July 2023 and July 2025, with assent from children and consent from parents. Those with neurodevelopmental disorders will be excluded. The investigators plan to recruit one in two eligible participants with T1D from our existing cohort, with a total sample size of 396 participants (264 cases and 132 controls), adequately powered to detect group differences with a moderate effect size.
Data on T1D exposure will be extracted from ongoing cohort records. Outcomes assessed in both groups include:
- Cognitive functions - assessed using age-appropriate tests.
- Behavioral and emotional problems - evaluated in children, adolescents, and young adults.
- Quality of life - assessed using standardized tools. Potential confounders such as age, gender, socio-economic status, parental education, occupation, participant's education, and pubertal status will be considered. Random blood samples will be collected at the time of cognitive testing to measure plasma glucose, HbA1c, and Human-BDNF levels, examining associations between glycemic control and cognitive outcomes. Additionally, annual checkup data will be used to explore the impact of T1D complications on cognitive function.
Group differences in outcomes will be analyzed using ANCOVA while controlling for covariates. Regression models will assess cognitive function as a function of T1D exposure, adjusting for mediators and modifiers.
This will be one of the first studies in India to systematically examine multiple cognitive domains in a large T1D sample across a broad age range (10-21 years). Findings will enhance understanding of T1D's impact on cognitive development in an Indian context, where undernutrition is common, and T1D prevalence is rising.
Keywords: Type 1 diabetes, children, cognitive function, behavioral and emotional problems, quality of life.
Detailed description
Objectives of the project:
- To assess cognitive function in children with T1D in comparison with healthy controls and its determinants (parental education and occupation, parenting style and mental health of parents)
- To study the association of parental education and occupation, parenting style and mental health of parents with child's glycemic control in children with T1D
- To assess the stress, anxiety and depression in children, adolescents and young adults with T1D (10-21 years) in comparison with healthy controls and its impact on their quality of life
- Methodology:
Study Subjects:
The 'Sweetlings' programme which is a charity clinic that provides holistic care to underprivileged children and youth with Type 1 Diabetes Mellitus (T1D). Currently, the clinic supports 548 children and youth with T1DM aged 0 to 22 years in the Pune region of the Western Indian State of Maharashtra.
The investigator have 382 children between 6-18 years of age and 103 who are between 18-22 years of age. Siblings of these T1D children will be included as healthy age matched controls for participation in this study. This will ensure about the age matching and also their socioeconomic status and family environment will be similar.
Sample size estimations:
The investigator expects to recruit one in two of participant with type 1 diabetes from our cohort and age gender matched healthy controls without type 1 diabetes. Sample size estimation suggests a sample size of 396 participants (264 cases and 132 controls) would be adequately powered to detect group differences with moderate effect size.
Procedure:
Institutional ethics committee approval will be obtained for the study. Children with T1D will be approached for participation and information about the study will be provided. T1D children and their parents will be recruited after obtaining informed parental consent from children less than 12 years and parent consent and child's assent for those above 12 years of age. Informed consent will be obtained from those above 18 years of age.
Exposures:
Systematic assessments of the exposures (Type 1 diabetes, Birth weight, parental education, occupation, mental health, parenting style) will be performed in the cohort. This data of recruited subjects will be extracted from available records as well as collecting their current information using a standardized questionnaire.
Glucose values and HbA1c measured in the clinic at the time of neurocognitive testing will be taken to study the associations between the glycemic control in T1D children and their neurocognitive outcomes.
Additionally, Brain Derived Neurotrophic Factor (BDNF) which is a key molecule involved in neuroplastic changes related to learning and memory will also be measured.
Outcomes:
Cognitive function and mental health of children, adolescents and young adults with T1D Following measurements will be performed in T1D children based on their age at assessment.
- Neurocognitive measurements: Global measures of intelligence was assessed using the Raven's progressive Matrices.
- Mental health in children and parents: Depression, anxiety and stress related information will be collected using specific questionnaires.
- Quality of life in children and parents using Peds QL standardised modules and questionnaires.
Cognitive function assessments (general intellectual test, IQ):
- Raven's Colored Progressive Matrices: Raven's Progressive Matrices (often referred to simply as Raven's Matrices) or RPM is a non-verbal test typically used to measure general human intelligence and abstract reasoning and is regarded as a non-verbal estimate of fluid intelligence.
- Speed: Finger tapping: It is the measure of motor speed. Age range: 9 years and above The finger-tapping test consists of an especially adopted electric finger-tapping instrument and monitor to read the number of taps.
- Attention: d2: It is a refinement of the cancellation test. Age range 9-60 years.
- Executive functioning:
- Verbal fluency: FAS test. Age range: Children: 5 to 15 years
- Animal names test: Age range: Children: 5 to 15 years
- COWA test (Controlled Oral Word Association test). Adults: 15 to 65 years
- Working memory: Digit and letter number (WISC). Age range: 6 to 16 years.
- Processing speed: Coding and symbol search (WISC). Age range: 6 to 16 years.
- Working memory: Digit and arithmetic (WAIS) [8] and Coding and symbol search (WAIS). Age range: 16 to 90 years
- Working Memory Index- subtests include Digit span and arithmetic. Processing Speed Index- subtests include symbol search, coding, and cancellation.
- Shift of set (Wisconsin card sorting test 64: Age range: 6 years 5 months to 89 years
- Response inhibition: Stroop test. Age range: Children: 5-14 years, Adults: 15 years and above
- Verbal learning and memory: Auditory verbal learning test (AVLT): Age range: Children: 5 to 15 years, Adults: 16 to 65 years
- Test of comprehension: Token test: Age range: Children: 5 to 15 years, Adults: 16 to 65 years
Mental health and quality of life in children and parents:
- CBCL (The Child Behavior Checklist): The 2001 revision of the CBCL, the CBCL/6-18 (used with children 6 to 18), is made up of eight syndrome scales:
- anxious/depressed
- depressed
- somatic complaints
- social problems
- thought problems
- attention problems
- rule-breaking behaviour
- aggressive behaviour
- BSI (Brief Symptom Inventory): The Brief Symptom Inventory (BSI) consists of 53 items covering nine symptom dimensions: Somatization, Obsession-Compulsion, Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic anxiety, Paranoid ideation and Psychoticism; and three global indices of distress: Global Severity Index, Positive Symptom Distress Index, and Positive Symptom Total. The global indices measure current or past level of symptomatology, intensity of symptoms, and number of reported symptoms, respectively.
- Quality of life:
Peds QL: The Pediatric Quality of Life Inventory (PedsQL): PedsQL Generic Core Scale will be used to measure generic health-related quality of life of the children, adolescents and young adults in this study. This scale is applicable for healthy school and community populations, as well as patient populations with acute and chronic health conditions.
Effect modifiers:
- Parents' mental health: This will be assessed using BSI questionnaire.
- Parenting style: The Parenting Styles and Dimensions Questionnaire (PSDQ)[19] is one measure that is widely utilized in current research to examine parenting styles.
- Parents' quality of life: PedsQL Generic Core Scale will be used to measure generic health-related quality of life of the primary caregiver (any one parent, either mother or father).
- Parental education and occupation: This information will be collected using standard questionnaires for general information.
- Scholastic performance: Academic exposure can positively impact cognitive functioning. This will be assessed by taking the average marks/grades obtained by the child in previous year academic performance.
Mediators:
- Glycemic control and complications of type 1 diabetes: The investigators regularly perform the annual checkups in our type 1 cohort. In that following measurements are performed to assess their glycemic control and development of micro and macrovascular complications.
- Human BDNF (Brain Derived Neurotrophic Factor): This will be measured using standard enzymatic method using Elabscience® Human BDNF (Brain Derived Neurotrophic Factor) ELISA Kit. Association between BDNF levels and cognitive functions will be studied.
- Growth and development: This data will be utilized from the anthropometric measurements performed at the time of their annual check-ups. Pubertal staging is performed by a pediatric endocrinologist or a medical officer. Information regarding age and date of menarche is also collected.
- Lifestyle (nutrition and physical activity): The investigators also collect the information regarding their nutritional intake using a 24-hour dietary recall and data regarding their physical activity levels using standard questionnaire. Using this data, the investigators can study the association between lifestyle with cognitive functions
Measurement of potential confounders:
- A semistructured proforma will be designed to collect socio-demographic information, current educational status, Parental education. Socio-economic status will be assessed using the Kuppuswamy 2023 coding and scale.
- Family history of neurodevelopmental/neurological/mental health disorders will be obtained on a three generation genogram.
- Pubertal status will be assessed on the Tanner's staging for Puberty by medical officer.
Future implications:
Early detection and intervention for cognitive impairment in the early stages of Type 1 Diabetes Mellitus (T1DM) can facilitate effective treatment. Cognitive impairment is closely linked to poor glycaemic control and associated metabolic disruptions in T1DM. Initiating the management of metabolic abnormalities during the initial phases of diabetes holds the potential to prevent cognitive impairment. It is essential to include cognitive impairment screening for individuals with T1DM alongside assessments for other recognised macro- and microvascular complications of diabetes.
In addition to evaluating children with T1D, conducting assessments for their parents, including an analysis of parenting styles and stress levels associated with managing their child's diabetes, allows for the strategic planning of interventions.
This holistic approach not only enhances parents' diabetes management but also contributes to improved glycaemic control in T1D children, thereby positively influencing their cognitive function.
Detecting and addressing cognitive impairment at an early stage not only aids in the effective management of diabetes in children but also plays a pivotal role in fostering improved career prospects and job opportunities for them. Additionally, this proactive approach contributes to an overall enhancement of their quality of life. The downstream effect of these positive outcomes includes a reduction in the health-related and economic burden faced by India.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 3 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Children and youth with type 1 diabetes (T1D) and their parents | – | –The Hirabai Cowasji Jehangir Medical Research Institute (HCJMRI), Pune is a Center of Excellence in type 1 diabetes and has vast experience in studying prospective cohorts with good follow up rates. It also has a registry of more than 800 children with type 1 diabetes with systematic assessment of their glycemic control and micro and macrovascular complications due to type 1 diabetes. We would like to propose a cross sectional, observational, case control study in children with T1D and healthy controls of age 10-21 years (who give assent and parents give consent; children no neurodevelopmental disorders will be enrolled in the study) from similar socio-economic class as the children with diabetes. Approximate period of enrollment will be from July 2023 to July 2025. We expect to recruit one in two of participant with type 1 diabetes from our cohort and age gender matched healthy controls without type 1 diabetes. |
Who may qualify
- Ages
- 10 to 21 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- Study Subjects: The Hirabai Cowasji Jehangir Medical Research Institute, which is a sister concern of Jehangir hospital, Pune, has been involved in health related programs since its inception in 1995. Our major areas of work include Nutritional and Growth Disorders in Children, Type 1 Diabetes, Maternal and Child Health, Osteoporosis and Bone Health, Psychological Counseling, HIV and Cancers. Cases: There are 738 children registered with HCJMRI for the treatment and management of type 1 diabetes. The 'Sweetlings' programme is a charity clinic that provides holistic care to underprivileged children and youth with Type 1 Diabetes Mellitus (T1D). Currently, the clinic supports 548 children and youth with T1D aged 0 to 22 years in the Pune region of the Western Indian State of Maharashtra. From these, we have 386 children who are between 10-21 years of age. Controls: Siblings of these T1D children will be included as healthy age-matched controls for participation in this study. This wil
Key inclusion criteria (1 listed)
- Children, adolescents and young adults with T1D and their parents (caregiver, either mother or father)
Key exclusion criteria (1 listed)
- Both parents are not alive or the child is not living with the parents and living with the grandparents.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To assess intelligent quotient (IQ) as a cognitive function in children and youth with type 1 diabetes
Time frame: 3 years
Age range: 4 to 90 years. Raven's Colored Progressive Matrices: Raven's Progressive Matrices (often referred to simply as Raven's Matrices) to measure general human intelligence and abstract reasoning and is regarded as a non-verbal estimate of fluid intelligence. The Raven's 2 is a nonverbal assessment of general cognitive ability, including the ability to formulate new concepts when faced with novel information, extract meaning out of confusion or ambiguity, and think clearly about complex situation and events. It comprises 60 multiple-choice questions, listed in order of increasing difficulty. This format is designed to measure the test taker's reasoning ability, the eductive ("meaning-making") component of Spearman's g (g is often referred to as general intelligence). It is a measure of verbal and nonverbal generalized cognitive ability.
To assess speed as a cognitive function in children and youth with type 1 diabetes
Time frame: 3 years
Finger-Tapping Test Age Range: 9 years and above Procedure: The test uses an adapted electric finger-tapping instrument and monitor to record the number of taps. The participant taps a mounted key as rapidly as possible using the index finger of the dominant hand, followed by the non-dominant hand. Five consecutive 10-second trials are conducted for each hand. A 30-second break is given after the third trial to minimize fatigue. A practice trial is provided before the test begins. Scoring: The number of taps per 10-second trial is recorded separately for each hand. The mean number of taps across five trials is calculated for each hand. Material: Finger-tapping instrument and stopwatch Duration: 5 minutes
To assess attention as a cognitive function in children and youth with type 1 diabetes
Time frame: 3 years
d2 Test of Attention Age Range: 9-60 years Procedure: The d2 test assesses selective attention and concentration. It can be administered individually or in groups using a single test form. The form includes sections for subject data, test scores, and a practice sample. The standardized test consists of 14 lines, each with 47 characters (total: 658 items). Participants scan each line and cross out all "d's" with two dashes. Each line is timed for 20 seconds. Reliability \& Validity: The test demonstrates high reliability (r > 0.90) across various indices (TN, TN-E, CP) and is supported by extensive research. Materials: 2 pencils (without erasers) and a stopwatch for the examiner. Duration: 10 minutes
To assess phonemic fluency as an executive function in children with type 1 diabetes
Time frame: 3 years
FAS Test (Children: 5-15 years) - A phonemic fluency test measuring verbal fluency. Participants generate words beginning with F, A, and S (or Ka, Pa, Ma for non-English speakers) within one minute per letter. Proper nouns are excluded. Score: Total admissible words. Duration: ~5 minutes
To assess category fluency as an executive function in children with type 1 diabetes
Time frame: 3 years
Animal Names Test (Children: 5-15 years) - A category fluency test where participants list as many animal names as possible in one minute, excluding fish, birds, and snakes. Score: Total unique words. Duration: ~5 minutes
To assess phonemic fluency as an executive function in adolescents and youth with type 1 diabetes
Time frame: 3 years
COWA Test (Adults: 15-65 years) - A phonemic fluency test where participants generate words beginning with F, A, and S (or Ka, Pa, Ma). Proper nouns and repeated words with different suffixes are excluded. Score: Average new words over three trials. Duration: ~5 minutes
To assess category fluency as an executive function in adolescents and youth with type 1 diabetes
Time frame: 3 years
Category Fluency: Animal Names Test (Adults: 15-65 years) - Same as the children's version, assessing category fluency. Score: Total unique words. Duration: ~5 minutes
To assess working memory as an executive function in children with type 1 diabetes
Time frame: 3 years
Digit \& Letter-Number (WISC) and Processing Speed: Coding \& Symbol Search (WISC) Age Range: 6-16 years Developed in 2003, this scale assesses intellectual ability. The Working Memory Index (WMI) includes Digit Span, Letter-Number Sequencing, and Arithmetic (supplemental). The Processing Speed Index (PSI) includes Coding, Symbol Search, and Cancellation (supplemental). Digit Span: The child repeats numbers in the same or reverse order. Letter-Number Sequencing: The child recalls numbers in ascending and letters in alphabetical order. Symbol Search: The child scans a group to identify target symbols within a time limit. Duration: 10 minutes
To assess working memory as an executive function in adolescents and youth with type 1 diabetes
Time frame: 3 years
Working Memory \& Processing Speed (WAIS) Age Range: 16-90 years The WMI measures working memory, attention, concentration, and reasoning, while the PSI assesses the ability to scan, sequence, and process visual information quickly. Both indices involve cognitive decision-making beyond simple reaction time. Duration: 20 minutes
To assess Shift of set (Wisconsin card sorting test) as an executive function in children and youth with type 1
Time frame: 3 years
Wisconsin Card Sorting Test (WCST-64) Age Range: 6 years 5 months to 89 years The WCST-64 assesses abstract reasoning and executive functions, including cognitive flexibility, goal-directed behavior, planning, and impulse control. Unlike the full WCST, which uses 128 cards, the WCST-64 uses 64 cards. Participants match stimulus cards without explicit instructions, receiving feedback on correctness. The test generates psychometric scores on categories achieved, trials, errors, and perseverative errors. Materials: Four stimulus cards, 64 response cards, and a record form. Duration: 20-30 minutes The WCST has demonstrated reliability and validity across various populations, including individuals with autism, stroke survivors, pediatric groups, and psychiatric patients.
To assess Response inhibition as an executive function in children and youth with type 1 diabetes
Time frame: 3 years
Stroop Test Age Range: Children (5-14 years), Adults (15+ years) The Stroop Test measures response inhibition, assessing the ability to suppress habitual responses in favor of unusual ones. It evaluates cognitive flexibility and prefrontal function. Participants are shown a sheet with color names ("Blue," "Green," "Red") printed in different ink colors. They first read the words column-wise as quickly as possible while the time is recorded. Next, they name the ink color instead of reading the word, with the time again recorded. Score: The Stroop effect score is calculated as: Stroop Effect Score = Time to name colors - Time to read words Uncorrected errors are recorded separately for both phases. Duration: ~20 minutes
To assess Verbal Learning and Memory as cognitive function in children and youth with type 1 diabetes
Time frame: 3 years
Verbal Learning \& Memory: Auditory Verbal Learning Test (AVLT) Age Range: Children (5-15 years), Adults (16-65 years) The AVLT assesses verbal learning and memory using word lists. Adapted by WHO for different cultures, it includes Lists A \& B with 15 familiar words each, translated into Kannada, Tamil, Telugu, and Hindi. Words from List A are presented at a rate of one per second for five trials, with recall recorded after each trial. Then, List B is introduced as an interference task, followed by immediate recall of List A. After 20 minutes, delayed recall of List A is assessed without re-presentation. Finally, a recognition test is conducted by mixing List A words with new words, recording hits and errors. Words are presented in the participant's preferred language (mother tongue or English). Duration: 15 minutes
To assess Test of comprehension as cognitive function in children and youth with type 1 diabetes
Time frame: 3 years
Test of Comprehension: Token Test Age Range: Children (5-15 years), Adults (16-65 years) The Token Test assesses verbal comprehension using tokens that vary in color, size, and shape. Participants follow spoken instructions of increasing complexity. Squares and circles in two sizes and five colors are placed in a fixed arrangement. Instructions are given once per item, with up to two repetitions if needed. Scoring: One point is awarded for correct responses, with a 0.5-point deduction per repetition. A trial is failed if the participant does not follow instructions after two repetitions. The maximum score is 36. Duration: 20 minutes
5 secondary outcomes
To assess mental health in children and youth with type 1 diabetes and their parents
Time frame: 3 years
To assess Diabetes related stress and quality of life in children and youth with type 1 diabetes
Time frame: 3 years
To assess parents' perception towards diabetes related stress and quality of life in their children
Time frame: 3 years
To assess general quality of life in children and youth with type 1 diabetes
Time frame: 3 years
To assess general quality of life in parents of children and youth with type 1 diabetes
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2025.
- Derived from this study: PubMed 42829215Wagle-Patki S, Keerthi A, Potnis R, Daphal Y, Gondhalekar K, Nayak IK, Kajale N, Vaman Khadilkar A. MIND-T1D: study protocol for a multidimensional neurocognitive and psychological assessment of Indian children and young adults with type 1 diabetes. BMJ Paediatr Open. 2026 Oct 3;10(1):e005159. doi: 10.1136/bmjpo-2026-005159.
- Individual participant dataSharing planned: Yes. The de-identified individual participant data (IPD) will be shared with qualified researchers. The shared data will include [specify data types, e.g., demographics, clinical outcomes, etc.]. Access will be granted to researchers with a scientifically sound proposal that has been reviewed and approved by an independent review board. Requests should be directed to [provide contact information or system, e.g., "via email to the principal investigator, Dr. Anuradha Khadilkar]. Data sharing will comply with applicable laws, regulations, and institutional policies to ensure privacy and data security.
Related trials for Type 1 Diabetes (T1D)
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Active, not recruitingPhase 4
Diabetes in African Youth
type1diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dr. Sonali S Wagle, M.Sc, RD, PhD study chair
Hirabai Cowasji Jehangir Medical Research Institute, Pune, India
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Type 1 Diabetes (T1D), run by Hirabai Cowasji Jehangir Medical Research Institute at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 10 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess intelligent quotient (IQ) as a cognitive function in children and youth with type 1 diabetes (time frame: 3 years). The study lists 13 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07164768, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2025.